Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Nakhle Saba, MD, associate professor of clinical medicine at Tulane University School of Medicine, discusses the significance of the key findings of the ELEVATE-TN trial (NCT02475681) of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).
The phase 3 multicenter trial randomized 535 patients with previously untreated CLL 1:1:1 to receive the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib plus obinutuzumab, acalabrutinib alone, or chlorambucil plus obinutuzumab. BTKis have previously showed efficacy first-line versus chlorambucil such as ibrutinib (Imbruvica) in the RESONATE-2 trial (NCT01722487).
Median progression-free survival (PFS) was not reached for either acalabrutinib arm at a median follow-up of 46.9 months versus 27.8 months for chlorambucil plus obinutuzumab. The results suggested that acalabrutinib plus obinutuzumab had prolonged PFS versus acalabrutinib alone, but the study was not powered to compare the 2 experimental arms. Saba says this is not enough evidence to suggest the combination will benefit patients over acalabrutinib alone.
Acalabrutinib was approved by the FDA based on these results as well as those of the ASCEND (NCT02970318), which enrolled patients with relapsed/refractory CLL to receive acalabrutinib monotherapy. Saba says that based on current data, he would not add an anti-CD20 such as obinutuzumab when giving a BTKi in the frontline or relapsed setting.
TRANSCRIPTION:
0:08 | We know that BTKi is superior to chemotherapy and that was reproduced in the ELEVATE-TN trial. The other key is whether an anti-CD20, particularly with regard to obinutuzumab—does it add anything to acalabrutinib single agent or not? So we know both arms, acalabrutinib plus [obinutuzumab] are superior to the chemoimmunotherapy arm, but what does obinutuzumab add to acalabrutinib? This study was not powered to look at that difference, although the odds ratio favors the combination with obinutuzumab over acalabrutinib alone. But this study was not powered to look at that difference.
So, for me, that’s still not convincing evidence that anti-CD20 adds any value to BTK alone in this particular setting. Acalabrutinib [is] awaiting more data, if any, I will see. But as of now, I would still favor if I’m using BTKI, either frontline or into relapse, I would not add an anti-CD20 to the mix unless with some very rare exceptions. But overall, I would not add it.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More